Propanc Biopharma, Inc. (PPCB)
0.6326
0.00 (0.00%)
USD |
NASDAQ |
Sep 18, 11:14
Propanc Biopharma Enterprise Value : 1.681M for Sept. 17, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 17, 2026 | 1.681M |
| September 16, 2026 | 1.685M |
| September 15, 2026 | 1.847M |
| September 14, 2026 | 1.873M |
| September 11, 2026 | 1.936M |
| September 10, 2026 | 1.955M |
| September 09, 2026 | 1.996M |
| September 08, 2026 | 2.031M |
| September 04, 2026 | 2.013M |
| September 03, 2026 | 2.022M |
| September 02, 2026 | 2.031M |
| September 01, 2026 | 2.118M |
| August 31, 2026 | 2.311M |
| August 28, 2026 | 2.311M |
| August 27, 2026 | 3.080M |
| August 26, 2026 | 2.066M |
| August 25, 2026 | 2.118M |
| August 24, 2026 | 2.140M |
| August 21, 2026 | 2.075M |
| August 20, 2026 | 2.092M |
| August 19, 2026 | 2.127M |
| August 18, 2026 | 2.144M |
| August 17, 2026 | 2.136M |
| August 14, 2026 | 2.197M |
| August 13, 2026 | 2.197M |
| Date | Value |
|---|---|
| August 12, 2026 | 2.188M |
| August 11, 2026 | 2.153M |
| August 10, 2026 | 2.136M |
| August 07, 2026 | 2.180M |
| August 06, 2026 | 2.319M |
| August 05, 2026 | 2.162M |
| August 04, 2026 | 2.022M |
| August 03, 2026 | 2.048M |
| July 31, 2026 | 2.013M |
| July 30, 2026 | 2.040M |
| July 29, 2026 | 1.996M |
| July 28, 2026 | 2.188M |
| July 27, 2026 | 2.284M |
| July 24, 2026 | 2.328M |
| July 23, 2026 | 2.398M |
| July 22, 2026 | 2.389M |
| July 21, 2026 | 2.337M |
| July 20, 2026 | 2.337M |
| July 17, 2026 | 2.433M |
| July 16, 2026 | 2.520M |
| July 15, 2026 | 2.556M |
| July 14, 2026 | 2.556M |
| July 13, 2026 | 2.529M |
| July 10, 2026 | 2.538M |
| July 09, 2026 | 2.687M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Immutep Ltd. | -- |
| CSL Ltd. | -- |
| Ceryvyn Therapeutics Ltd. | -- |
| Mesoblast Ltd. | 1.973B |
| Actinogen Medical Ltd. | -- |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.360M |
| Total Expenses (Quarterly) | 6.360M |
| EPS Diluted (Quarterly) | -7.09 |
| Earnings Yield | -5.25K% |
| Normalized Earnings Yield | -5446.78 |